Latest MS research news

Latest MS research news | 10 June 2014

Extensive white matter dysfunction in cognitively impaired patients with secondary-progressive MS

These findings suggest that cognitive impairment during the progressive phase of MS is mainly due to diffuse white matter injury superimposed on a background of cognition-specific tract damage sustained during earlier stages.

From MSIF

Latest MS research news | 27 May 2014

JC Virus in CD34 and CD19 cells in MS patients treated with natalizumab

In this study JCV DNA was detected within the cell compartments of natalizumab-treated MS patients after treatment inception and after 24 months. Continued studies are needed to further investigate natalizumab treatment as the mechanism of progressive multifocal leukoencephalopathy.

From MSIF

Latest MS research news | 27 May 2014

Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis

The results of this study show that no clinical or demographic predictors are significantly associated with severity of acute optic neuritis, while male sex and attack severity are independently associated with recovery.

From MSIF

Latest MS research news | 27 May 2014

Natalizumab use during the third trimester of pregnancy

These case series show that exposure to natalizumab during the third trimester of pregnancy in women with aggressive multiple sclerosis led to hematological abnormalities in 10 of the 13 newborns (i.e. thrombocytopenia, anemia, and leukocytosis).

From MSIF

Latest MS research news | 20 May 2014

Final results from the Betaseron Pregnancy Registry

This prospective observational study does not find any patterns to suggest negative pregnancy outcomes associated with interferon β-1b exposure. However, continued monitoring through routine postmarketing surveillance activities is recommended.

From MSIF

Latest MS research news | 20 May 2014

Two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting MS

In the current study miR-326 expression level was significantly elevated in the relapsing phase patient group compared with remitting phase patients and healthy groups. More studies in larger scales are needed to confirm this expression cutoff point for clinical use of miR-326 in RR-MS patients.

From MSIF

Latest MS research news | 20 May 2014

Gray matter atrophy in longstanding multiple sclerosis

Whole-brain and deep gray matter atrophy are particularly explained by white matter atrophy and lesion volume, while cortical atrophy was associated with normal-appearing white matter integrity loss.

From MSIF

Latest MS research news | 12 May 2014

Identical lesion morphology in primary progressive and relapsing-remitting MS - an ultrahigh field MRI study

This study shows that cortical grey matter damage is equally common in primary progressive and relapsing remitting multiple sclerosis.

From MSIF

Latest MS research news | 12 May 2014

The RESTORE trial: What did we learn about multiple sclerosis?

Results from RESTORE study suggest that planned dosage interruption of natalizumab is likely not to be useful for the management of most patients switching to no treatment or to the disease-modifying therapies employed in this study.

From MSIF

Latest MS research news | 12 May 2014

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE)

Subcutaneous peginterferon beta-1a 125 μg administered every two weeks significantly reduced annualised relapse rate at 48 weeks, relapses and the risk of disability progression over 48 weeks, the number of T2 lesions at 48 weeks compared with placebo.

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial